2 recruiting, 1 active not recruiting, 1 unknown. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Aggressive B-Cell Non-Hodgkin Lymphoma: new trials by email Literature Review of Aggressive B-Cell Non-Hodgkin Lymphoma trials Research Report on Aggressive B-Cell Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma EMB07, Rituximab/Gemcitabine/Oxaliplatin - Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Shanghai EpimAb Biotherapeutics Co., Ltd. | 115 | 2026-04-01 | 2026-09-01 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma CD47 Antagonist ALX148, Lenalidomide, Rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2021-10-13 | 2026-09-18 |
| A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma fractionated first dose rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma | Unknown | University Hospital, Geneva | 94 | 2020-08-24 | 2023-05-06 |
Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Composite Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Pyloric Stenosis, Hypertrophic (1) · Tumor Lysis Syndrome (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Lymphoma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Digestive System Diseases (1) · Gastric Outlet Obstruction (1) · Gastrointestinal Diseases (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1)
Rituximab (2) · ALX148 (1) · CT-P10 (1) · Lenalidomide (1) · gemcitabine-oxaliplatin regimen (1)
M.D. Anderson Cancer Center (1) · Shanghai EpimAb Biotherapeutics Co., Ltd. (1) · University Hospital, Geneva (1) · Verismo Therapeutics (1)
United States (2) · China (1) · Switzerland (1)
Laura A Johnson, PhD (1) · Noemie Lang, MD (1) · Paolo Strati, MD (1)